Also found in: Dictionary, Wikipedia.
Related to Seroquel: Quetiapine

quetiapine fumarate

Seroquel, Seroquel XR

Pharmacologic class: Dibenzothiazepine derivative

Therapeutic class: Atypical antipsychotic

Pregnancy risk category C


Unknown. Antipsychotic effects may occur through antagonism of dopamine D2 and serotonin 5-HT2 receptors. Other effects may result partly from antagonism of other receptors, such as histamine H1 and alpha1-adrenergic receptors.


Tablets: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg

Tablets (extended-release): 50 mg, 150 mg, 200 mg, 300 mg, 400 mg

Indications and dosages


Adults: Initially, 25 mg P.O. b.i.d., on day 1, increased by 25 to 50 mg given two to three times daily on days 2 and 3 to range of 300 to 400 mg by day 4. Further adjustments can be made in increments of 25 to 50 mg b.i.d. in intervals of not less than 2 days. Recommended dosage range is 150 to 750 mg/day. Or, 300 mg P.O. (extended-release tablet) once daily, preferably in evening; dosage should be titrated to 400 to 800 mg based on response and tolerability. Dosage increases may be done at 1-day intervals at increments of up to 300 mg.

Children and adolescents ages 13 to 17: Immediate-release tablets administered twice daily, with total daily dosage for initial 5 days of therapy as 50 mg P.O. on day 1, 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and 400 mg on day 5. After day 5, adjust dosage within recommended range of 400 to 800 mg/day based on response and tolerability. Make dosage adjustments in increments of no greater than 100 mg/day. Based on response and tolerability, may administer three times daily.

Acute manic episodes associated with bipolar I disorder

Adults: Immediate-release tablets administered twice daily, with total daily dosages as 100 mg P.O. on day 1, 200 mg on day 2, 300 mg on day 3, and 400 mg on day 4. Increase in increments of no more than 200 mg/day up to 800 mg/day by day 6. Recommended dosage range is 400 to 800 mg/day. May be given as monotherapy or as adjunctive therapy with lithium or divalproex. Or, extended-release tablets 300 mg P.O. on day 1,600 mg on day 2, and 400 to 800 mg on day 3. Recommended dosage range is 400 to 800 mg/day.

Children and adolescents ages 10 to 17: Immediate-release tablets administered twice daily, with total daily dosage for initial 5 days of therapy as 50 mg P.O. on day 1,100 mg on day 2, 200 mg on day 3,300 mg on day 4, and 400 mg on day 5. After day 5, adjust dosage within recommended range of 400 to 600 mg/day based on response and tolerability. Adjust dosage in increments of no more than 100 mg/day. Based on response and tolerability, may administer three times daily.

Depression associated with bipolar disorder

Adults: Immediate-release or extended-release tablets administered once daily at bedtime as 50 mg P.O. on day 1, 100 mg on day 2, 200 mg on day 3, and 300 mg on day 4. Maximum dosage is 300 mg/day.

Adjunctive treatment of major depressive disorder

Adults: Initially, 50 mg (extended-release) P.O once daily in the evening on days 1 and 2 and 150 mg (extended-release) P.O. once daily on days 3 and 4 as adjunct to existing antidepressive therapy. Recommended dosage is 150 to 300 mg/day.

Dosage adjustment

• Hepatic impairment
• History of hypotensive reactions
• Elderly or debilitated patients

Off-label uses

• Bipolar disorder
• Mania
• Obsessive-compulsive disorder
• Posttraumatic stress disorder
• Psychosis related to Parkinson's disease


• None


Use cautiously in:
• diabetes mellitus, hepatic impairment, cardiovascular disease (including family history of QT-interval prolongation, congestive heart failure, and cardiac hypertrophy), cerebrovascular disease, dehydration, hypovolemia, Alzheimer's dementia, hypothyroidism
• history of seizures, suicide attempt, or hypotensive reactions
• history of cardiac arrhythmias such as bradycardia, hypokalemia or hypomagnesemia, concurrent use of other drugs that prolong the QTc interval, congenital QT-interval prolongation (avoid use)
• concurrent use of drugs known to cause electrolyte imbalance
• elderly or debilitated patients
• pregnant patients
• children (safety not established).


• Monitor fasting blood lipids before treatment.
• Give immediate-release tablets with or without food; give extended-release tablets without food or with a light meal.

Don't confuse Seroquel with Serzone (an antidepressant).

Adverse reactions

CNS: dizziness, sedation, cognitive impairment, extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, seizures, suicide

CV: tachycardia, palpitations, peripheral edema, ­orthostatic hypotension, hypertension, QT-interval prolongation

EENT: cataracts, ear pain, rhinitis, pharyngitis

GI: constipation, dyspepsia, dry mouth, anorexia

Hematologic: leukopenia

Metabolic: hypothyroidism

Respiratory: cough, dyspnea

Skin: diaphoresis

Other: weight gain, flulike symptoms, acute withdrawal symptoms with abrupt cessation


Drug-drug.Antihistamines, opioids, sedative-hypnotics, other CNS depressants: additive CNS depression

Antibiotics (such as gatifloxacin, moxifloxacin), antipsychotics (such as chlorpromazine, thioridazine, ziprasidone), Class 1A antiarrhythmics (such as procainamide, quinidine), Class III antiarrhythmics (such as amiodarone, sotalol), drugs known to prolong QTc interval (such as levomethadyl acetate, methadone, pentamidine): increased risk of prolonged QTc interval

Antihypertensives: increased risk of hypotension

Barbiturates, carbamazepine, corticosteroids, phenytoin, rifampin, thioridazine: increased clearance and decreased efficacy of quetiapine

Dopamine agonists, levodopa: antagonism of these drugs' effects

Erythromycin, fluconazole, itraconazole, ketoconazole, other CYP450-3A4 inhibitors: increased quetiapine effects

Drug-diagnostic tests.Alanine aminotransferase, aspartate aminotransferase: asymptomatic elevations

Total cholesterol, triglycerides: increased levels

Urine tricyclic antidepressant assay: false-positive screen

White blood cells: decreased count

Drug-behaviors.Alcohol use: increased CNS effects

Patient monitoring

Monitor neurologic status, especially for signs and symptoms of tardive dyskinesia, suicidal ideation, or neuroleptic malignant syndrome.
• Be aware that patient should undergo lens examination when starting treatment and at 6-month intervals during long-term treatment.
• Monitor blood pressure for orthostatic hypotension.

Monitor patient closely for prolonged QT interval.
• Monitor fasting blood lipids periodically during treatment.

Monitor CBC and differential in patients with preexisting low white blood cell (WBC) count; discontinue drug at first sign of WBC decrease in absence of other causes.

Patient teaching

• Tell patient to take immediate-release tablets with or without food and to take extended-release form preferably in the evening, swallowed whole, without food or with a light meal.
• Instruct patient not to crush, break, or chew extended-release tablets.

Teach patient to recognize and immediately report signs and symptoms of neuroleptic malignant syndrome (such as high fever, sweating, unstable blood pressure, stupor, muscle rigidity, changes in mood or behavior and tardive dyskinesia) and prolonged QT interval.
• Instruct patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.

Tell patient not to stop taking drug abruptly. Tell him dosage must be tapered.
• Caution patient not to drink alcohol.
• Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.


A trademark for the fumarate salt of the drug quetiapine.


Quetiapine, see there.


A brand name for QUETIAPINE.

Patient discussion about Seroquel

Q. Is 700 mg of seroquel too much? My husband has prescriptions for seroquel. He is to take 600 mg at bedtime. He becomes lathargic. Many times he takes and extra 100 mg of seroquel and goes into a stuper like condition. What can happen?

A. Somnolence is a well-know side effect of Seroquel, so it’s not surprising. In addition, the dosage you specified seems within normal range. However, dosage may need personal adjustment, and since making this through the net is neither successful nor responsible, I’d suggest consulting a professional (e.g. his doctor) and discuss these issues with him or her.

Q. I have bipolar and the meds im on are; lithium, seroquel, lamictal. i just found out im six weeks pregnant is there damage?

A. correct links:

More discussions about Seroquel
References in periodicals archive ?
Among Widely Used Atypical Antipsychotics, Bristol-Myers Squibb's Abilify Effectively Competes With AstraZeneca's Seroquel Despite a Lack of Approval for the Treatment of Bipolar Depression, According to New Analysis from Decision Resources
Detailed information on Seroquel XR including product description, safety and efficacy profiles as well as a SWOT analysis.
The court dismissed AstraZeneca's bid to expand patents on the medication's active ingredient, quetiapine, and on the formula for Seroquel XR, the extended-release version.
Reckitt Benckiser, manufacturer of Nurofen Plus, could not rule out sabotage last night and said "serious investigations" are under way to establish how the errors occurred, especially as Seroquel XL is manufactured by another drug firm, AstraZeneca.
Seroquel XL is a prescriptiononly anti-psychotic drug used to treat several disorders, including schizophrenia, mania and bipolar depression.
Seroquel is officially approved for treating schizophrenia and bipolar disorder, but it is widely prescribed for unapproved uses, including other psychiatric conditions and insomnia.
SEROQUEL XR has been developed with the aim of improving dosing and titration options for patients and their doctors as they face the challenge of achieving successful treatment of schizophrenia.
The submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) was widely expected in the City after AstraZeneca trumpeted the results of trials involving Seroquel in October.
Lead researcher Prof Clive Ballard, who began the project while working at Newcastle University, said: "Our research has revealed that far from being safe Seroquel is potentially very dangerous for Alzheimer's sufferers.
This follows a decision made in the UK on March 22, 2012, which found the formulation patent protecting SEROQUEL XR to be invalid.
The London-based company faces about 9,000 lawsuits claiming it failed to properly warn users that Seroquel can cause diabetes, high blood sugar and other health issues.
Among clinically stable patients who switched from original formulation quetiapine, there were no significant differences between SEROQUEL sustained release formulation and the original formulation quetiapine in PANSS total scores after 6 weeks treatment (mean PANSS total score at day 42 was 55.